Immediate Impact
10 standout
Citing Papers
Claudin 18.2 as a novel therapeutic target
2024 Standout
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
Works of C. Heinz being referenced
Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| C. Heinz | 100 | 45 | 4 | 56 | 53 | 7 | 145 | |
| D. Huss | 106 | 33 | 28 | 53 | 51 | 15 | 217 | |
| Margherita Casiraghi | 158 | 149 | 19 | 52 | 14 | 199 | ||
| R. Scardaoni | 29 | 18 | 1 | 39 | 53 | 6 | 130 | |
| M. John | 55 | 29 | 3 | 48 | 52 | 12 | 109 | |
| O.H. Odland | 134 | 102 | 4 | 75 | 36 | 14 | 207 | |
| M. Mosconi | 84 | 41 | 6 | 44 | 17 | 16 | 125 | |
| Khayrullo Shoniyozov | 158 | 180 | 8 | 10 | 116 | 13 | 236 | |
| L. Sihver | 99 | 93 | 15 | 49 | 10 | 176 | ||
| D. H. Moon | 51 | 17 | 9 | 13 | 105 | 10 | 149 | |
| T. J. Radcliffe | 93 | 50 | 23 | 48 | 8 | 140 |
All Works
Loading papers...